Dana dhuwit diétung saben saham Plus Therapeutics Inc (PSTV)

Lambang korporat lan logo Plus Therapeutics (PSTV)

The annual trend of cash per share for Plus Therapeutics, Inc. (PSTV) demonstrates current liquidity levels, with the metric holding around 2.20. Growth is hindered by stringent FDA oversight and radiotherapy patent protections. Prospects rely on the targeted irradiation of complex tumors; however, business success is tied to clinical trial results and the rate of capital burn before reaching stable profitability.

Plus Therapeutics Inc (PSTV) - Dhuwit awis saben siji saham saka 04.07.2022 nganti 03.08.2026

Rincian metrik komprehensif lan analitis Plus Therapeutics Inc (PSTV)

- rega lan prakiraan konsensus rega:
- rincian posisi dhuwit lan arus kas:
Analisis komprehensif perusahaan:Plus Therapeutics - PSTV
Barang unggulan Plus Therapeutics

Long-term risk control requires diligent liquidity monitoring to ensure business viability. This is critical for Plus Therapeutics, Inc. (PSTV), as the development of radiotherapeutic drugs demands colossal expenditures for clinical trials. The cash per share history reflects the remaining net cash per security after all debts are settled. An increase in this indicator confirms financial stability, while a decrease signals a risk of equity dilution. This metric determines the company's autonomy horizon until the next funding round.